Research News for the Second Two Months of 2026

This is the thirty-sixth article in the project, which aims to periodically (every two months) collect research news on potential treatments for glioblastoma multiforme. Below, we list the news items we consider most significant that have emerged in the last two months. As with previous articles in the series, each news item will be preceded by the original title with a link to the source and followed by a brief commentary. The criteria for selecting news items is always to generally include only news related to clinical-stage research, unless the potential for research in the treatment of glioblastoma is truly significant.

Advanced Brain Cancer Survival Rates Double with LITT
A Phase I/IIb study, led by Dr. David Tran and colleagues, tested the combination of laser interstitial thermal therapy (LITT) with the immunotherapy drug pembrolizumab in patients with recurrent high-grade gliomas, including GBM. All patients were in at least their second recurrence, and many were in their third or later recurrence. LITT removes tumor tissue using heat and temporarily opens the blood-brain barrier; this study demonstrated that it also activates non-classical immune monocytes, paving the way for an enhanced response from pembrolizumab. The results are remarkable: compared to conventional surgery followed by pembrolizumab, the LITT + pembrolizumab combination more than doubled median overall survival (from 5.2 to 11.8 months) and progression-free survival (from 1.6 to 4.5 months) in the per-protocol population. In the specific subgroup of patients with IDH-wildtype GBM, median survival increased from 4.8 to 11.1 months. Perhaps most strikingly, 42% of patients treated with the combination were still alive at 18 months, and over a third survived beyond three years—an extraordinary result for a population with such advanced disease. These data indicate that LITT is not merely a surgical tool but can become a powerful primer of the tumor’s immune microenvironment, paving the way for new immunotherapy combinations.

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
The large, adaptive Phase II/III GBM AGILE trial—one of the most ambitious and methodologically advanced research projects in GBM—has published final results for the arm dedicated to regorafenib (Stivarga), an oral multikinase inhibitor already approved for other tumors. The drug was evaluated in two settings: in recurrent GBM (compared to lomustine) and in newly diagnosed, unmethylated GBM (compared to standard chemoradiation). In both cases, regorafenib demonstrated no advantage in terms of overall survival and was associated with greater toxicity than the control arm. The data are disappointing but not entirely unexpected: the previous phase 2 REGOMA trial had already shown a weak and controversial signal in recurrent GBM, and the transition to a randomized phase 2/3 evaluation definitively clarified the issue. The result fits a recurring pattern in the history of GBM: monotherapies with tyrosine kinase inhibitors have repeatedly failed to translate early signals into lasting clinical benefits, due to the complexity and redundancy of the signaling pathways that drive glioblastoma progression. From a methodological standpoint, however, GBM AGILE has demonstrated its effectiveness: thanks to the adaptive Bayesian design, it was possible to exclude regorafenib as a therapeutic option more quickly and with fewer patients than would be the case in a traditional trial, freeing up resources to evaluate more promising agents.

GCAR and Purdue Pharma Announce Initiation of Tinostamustine in GBM AGILE Trial
Also as part of the adaptive GBM AGILE trial, the initiation of a new experimental arm dedicated to tinostamustine was announced. This investigational drug is particularly interesting for its dual mode of action in a single molecule: it combines DNA alkylation activity—similar to that of temozolomide, which can damage tumor genetic material and induce cell death—with the inhibition of histone deacetylases (HDACs), an epigenetic mechanism capable of making the tumor more sensitive to therapy and potentially more recognizable by the immune system. Previous Phase 1 studies have shown a manageable safety profile. Inclusion in GBM AGILE allows for rapid and efficient assessment of clinical benefit in both newly diagnosed and established patients.
Recurrent GBM, leveraging the shared control arm and the trial’s adaptive statistical design to accelerate conclusions. As with other drugs evaluated in the GBM AGILE trial, the continuous data monitoring mechanism will allow the arm to be stopped early if negative signals are detected or its evaluation to be accelerated if promising results are seen.

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
Telix Pharmaceuticals announced the treatment of the first patient in the randomized Phase 3 IPAX-BrIGHT trial evaluating TLX101-Tx for recurrent GBM. This represents a historic milestone: in the last 25 years, only two drugs have received FDA approval for GBM, and no Phase 3 trial of a radiopharmaceutical has ever been initiated for this indication. TLX101-Tx is an iodine-131-labeled amino acid, a form of targeted internal radiotherapy that exploits a biological characteristic of glioblastoma cells: their high and selective uptake of amino acids compared to healthy brain tissue. This property allows the drug to preferentially concentrate in the tumor, delivering the radioactive dose directly to the tumor cells and reducing exposure to surrounding brain tissue. The approach fits into the emerging category of radioligand therapies—already revolutionary in prostate oncology with drugs such as lutetio-PSMA—and the IPAX-BrIGHT trial represents the first systematic attempt to advance this strategy to Phase 3 in GBM. The results of this study, expected to be one of the most significant in neuro-oncology in the coming years, could redefine therapeutic options for patients with recurrent GBM.

Plixorafenib Receives FDA Breakthrough Therapy Designation for BRAF V600E-Mutated High Grade Glioma
The FDA has granted Breakthrough Therapy Designation (BTD) to plixorafenib, an oral RAF inhibitor, for patients with recurrent high-grade gliomas harboring the BRAF V600E mutation. BTD is a regulatory designation reserved for drugs that show preliminary evidence of substantial superiority over existing therapies for serious conditions; it provides for an accelerated development pathway with intensive guidance from the FDA. The designation is based on particularly encouraging preliminary clinical data: in a predefined subgroup of nine patients with BRAF V600E-mutated primary central nervous system tumors—including high-grade gliomas—who had not previously received similar agents, 67% showed measurable tumor reduction and over 75% achieved a clinical benefit (objective response or stable disease). Considering all BRAF V600-mutated solid tumors in the trial, the overall response rate was 42%, with a median duration of response of 17.8 months and a generally favorable safety profile. The BRAF V600E mutation is present in a relatively limited subpopulation of high-grade gliomas, but currently available treatment options for these patients are limited, making plixorafenib a potential breakthrough in precision medicine applied to neuro-oncology. An ongoing Phase 2 trial is further evaluating its efficacy in BRAF-mutated tumors, including brain tumors.

Gibson Oncology Moves into Phase 2 Studies of LMP-744
Gibson Oncology has announced the initiation of a Phase 2 study with LMP-744, an investigational drug with a dual mechanism of action, in first-relapse GBM. LMP-744 acts on two distinct targets: it inhibits topoisomerase-1, an enzyme essential for tumor DNA replication (already targeted by irinotecan, a drug used in some therapies for recurrent GBM), and simultaneously suppresses the oncoprotein cMYC, a transcription factor that actively promotes tumor cell proliferation and has long been considered a highly desirable therapeutic target but historically undruggable with conventional approaches. It is administered intravenously, once daily for 5 consecutive days per month—a relatively patient-friendly schedule. In previous Phase 1 studies, LMP-744 demonstrated an acceptable safety profile, justifying the move to Phase 2. The trial focuses on first-relapse GBM, a population with very few established therapeutic options and where lomustine remains the de facto standard despite very limited response rates. Advancement to Phase 2 represents a significant step for this molecule, which aims to offer a rational alternative based on well-defined molecular targets.

That’s all for the second quarter of 2026. A heartfelt thank you to all those whose support allows us to keep this volunteer organization alive. We are committed to continuing to develop projects increasingly focused on providing concrete support to patients and their caregivers. Thanks to the Friuli Venezia Giulia Region, the “Speranza e Coraggio” project has been extended for another year! Today, this project represents an active resource used by those who have chosen not to face this journey alone: ​​a specialized psychological support service designed to accompany patients and their families through the most difficult times. If you are experiencing glioblastoma directly or indirectly, we invite you to take advantage of this completely free service: asking for help is an act of strength.

To all those fighting glioblastoma, and to their loved ones, our deepest sympathies go out.